eicosapentaenoic acid ethyl ester has been researched along with Coronary Artery Disease in 7 studies
Coronary Artery Disease: Pathological processes of CORONARY ARTERIES that may derive from a congenital abnormality, atherosclerotic, or non-atherosclerotic cause.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Though statin therapy is known to slow coronary atherosclerosis progression and reduce cardiovascular (CV) events, significant CV risk still remains." | 3.01 | Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: a prospective, placebo-controlled randomized trial (EVAPORATE): interim results. ( Bhatt, DL; Budoff, MJ; Kinninger, A; Lakshmanan, S; Le Pa, VT; May, HT; Muhlestein, JB; Nelson, JR; Roy, SK; Shaikh, K; Shekar, C; Tayek, J, 2021) |
| "Patients had to have coronary atherosclerosis as documented by MDCT (one or more angiographic stenoses with ≥20% narrowing), be on statin therapy, and have persistently elevated triglyceride (TG) levels." | 2.94 | Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial. ( Bhatt, DL; Budoff, MJ; Kinninger, A; Lakshmanan, S; Le, VT; May, HT; Muhlestein, JB; Nelson, JR; Roy, SK; Shaikh, K; Shekar, C; Tayek, J, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 5 (71.43) | 2.80 |
| Authors | Studies |
|---|---|
| Chapman, MJ | 1 |
| Zamorano, JL | 1 |
| Parhofer, KG | 1 |
| Rabbat, MG | 1 |
| Lakshmanan, S | 3 |
| Benjamin, MM | 1 |
| Doros, G | 1 |
| Kinninger, A | 3 |
| Budoff, MJ | 3 |
| Bhatt, DL | 3 |
| Muhlestein, JB | 2 |
| Le Pa, VT | 1 |
| May, HT | 3 |
| Shaikh, K | 2 |
| Shekar, C | 2 |
| Roy, SK | 2 |
| Tayek, J | 2 |
| Nelson, JR | 3 |
| Le, VT | 2 |
| Tokgozoglu, L | 1 |
| Catapano, AL | 1 |
| Budoff, M | 1 |
| Brent Muhlestein, J | 1 |
| Roy, S | 1 |
| Lan, NSR | 1 |
| Fegan, PG | 1 |
| Yeap, BB | 1 |
| Rankin, JM | 1 |
| Watts, GF | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Study of the Effect of Eicosapentaenoic Acid (EPA) on Markers of Atherothrombosis in Patients With Type-2 Diabetes[NCT06129526] | Phase 4 | 450 participants (Anticipated) | Interventional | 2023-12-31 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for eicosapentaenoic acid ethyl ester and Coronary Artery Disease
| Article | Year |
|---|---|
Reducing residual cardiovascular risk in Europe: Therapeutic implications of European medicines agency approval of icosapent ethyl/eicosapentaenoic acid.
Topics: Adult; Atherosclerosis; Cardiovascular Diseases; Coronary Artery Disease; Eicosapentaenoic Acid; Hea | 2022 |
3 trials available for eicosapentaenoic acid ethyl ester and Coronary Artery Disease
3 other studies available for eicosapentaenoic acid ethyl ester and Coronary Artery Disease
| Article | Year |
|---|---|
Benefit of icosapent ethyl on coronary physiology assessed by computed tomography angiography fractional flow reserve: EVAPORATE-FFRCT.
Topics: Computed Tomography Angiography; Coronary Angiography; Coronary Artery Disease; Coronary Stenosis; C | 2023 |
Can EPA evaporate plaques?
Topics: Coronary Artery Disease; Eicosapentaenoic Acid; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibito | 2020 |
Icosapent ethyl for dyslipidaemia in patients with diabetes and coronary artery disease: Act now to reduce it.
Topics: Aged; Coronary Artery Disease; Diabetes Mellitus, Type 2; Dyslipidemias; Eicosapentaenoic Acid; Fema | 2019 |